The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Need to harmonize traditional and modern medicine to combat alarming health problems
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
CiplaMed 2.0 leverages advanced analytics and automation
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Subscribe To Our Newsletter & Stay Updated
